User:Mr. Ibrahem/Naloxegol
 | |
| Clinical data | |
|---|---|
| Trade names | Movantik, Moventig |
| Other names | PEGylated naloxol;[1] NKTR-118 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | ~4.2% |
| Metabolism | Liver (CYP3A) |
| Elimination half-life | 6–11 h |
| Excretion | Feces (68%), urine (16%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C34H53NO11 |
| Molar mass | 651.794 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Naloxegol, sold under the brand names Movantik and Moventig, is a medication used for opioid-induced constipation in people with long term non-cancer pain.[2] It may be used when laxatives are not effective.[3] It is taken by mouth.[2] It generally dose not affect pain management.[3]
Common side effects include abdominal pain, diarrhea, nausea, and headache.[2] Other side effects may include opioid withdrawal and gastrointestinal perforation.[2] Use in pregnancy has not shown harm; however such use has not been well studied.[4] Chemically it is naloxone attached to polyethylene glycol (PEF).[2] It is a peripherally acting μ-opioid receptor antagonist, which prevents opioids from binding to receptors in the gut.[2]
Naloxegol was approved for medical use in the United States and Europe in 2014.[2][5] In the United States it costs about 360 USD per month as of 2021.[6] This amount in the United Kingdom costs the NHS about £55.[3] As of 2015 it is no longer a controlled substance in the United States.[7]
References[edit]
- ^ Seifert R, Wieland T, Mannhold R, Kubinyi H, Folkers G (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Archived from the original on 28 June 2014. Retrieved 14 May 2012.
- ^ a b c d e f g "Naloxegol Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 11 November 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 71. ISBN 978-0857114105.
- ^ "Naloxegol (Movantik) Use During Pregnancy". Drugs.com. Archived from the original on 27 January 2021. Retrieved 11 November 2021.
- ^ "Moventig". Archived from the original on 27 February 2021. Retrieved 11 November 2021.
- ^ "Naloxegol Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 31 October 2016. Retrieved 11 November 2021.
- ^ "Schedules of Controlled Substances: Removal of Naloxegol From Control". www.deadiversion.usdoj.gov. Archived from the original on 2016-03-09. Retrieved 2016-02-27.